Ferumoxytol Non-Stoichiometric Magnetite
PreclinicalSmall molecule
Ferumoxytol Non-Stoichiometric Magnetite is one of 56 small molecule programs targeting Glioblastoma Multiforme. It is currently in Preclinical.
1
Indications
2
Total Trials
0
Active Trials
55
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
292 competitors in Glioblastoma Multiforme
#DrugCompanyPhaseTrials
1Bicnu
MMelissa K Accordino
Phase 3
Arava
SanofiPhase 3
Aralen
SanofiPhase 3
Ceenu
AAzurity Pharmaceuticals
Phase 3
Opdivo
Bristol-Myers SquibbPhase 3
Yervoy
Bristol-Myers SquibbPhase 3
Veliparib
AbbViePhase 3
Theraplaza
BBiotech Pharmaceutical Co., Ltd.
Phase 3
Enzastaurin
Eli LillyPhase 3
Thalomid
Bristol-Myers SquibbPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- OOHSU Knight Cancer Institute